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Sir,
Your correspondents’ main assertion is that our estimate of lead
time in breast screening is too large due to the inclusion of all
breast cancer cases in its estimation and that as a consequence our
estimate of overdiagnosis is too small. First, we explicitly stated
that our excess incidence of 39% was not claimed to estimate
overdiagnosis, so they are mistaken on that count. Secondly, we do
not find their argument about lead time persuasive, as our estimate
of 2.4 years is consistent with sojourn time estimates from studies
that used heterogeneity models allowing for some cancers never to
progress (Duffy et al, 2005; Olsen et al, 2006).
Your correspondents’ preferred approach (Zahl et al, 2004) of
comparing the rise in incidence in a screened age group with the
drop in incidence at higher ages is similarly unconvincing because,
as was pointed out in the British Medical Journal rapid response
columns at the time, there was inaccurate specification of screened
age groups, insufficient time for the subsequent drop in incidence
to be observed and insufficient attention was paid to other factors
(notably hormone replacement therapy use).
We are also sceptical about their assertions concerning over-
diagnosis in the Malmo ¨ Trial. They cite screening in the control
group but fail to consider continued voluntary screening in the
study group after invitations had ceased.
Whether it is convenient or not for us and for your
correspondents, methodological complexities such as lead time
are highly influential in the observed incidence during a screening
programme. Failure to take these into account leads to implausibly
high estimates of the order asserted by your correspondents.
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